On Tuesday, October 21, 2014 the Pulmonary-Allergy Drugs Advisory Committee (PADAC) will discuss supplemental new drug application (sNDA) 203188,Kalydeco (ivacaftor) oral tablets, submitted by Vertex Pharmaceuticals Inc., for the treatment of cystic fibrosis in patients with an R117H mutation in the cystic fibrosis transmembraneconductance regulator gene.